Many companies expect that shifting to decentralised clinical trials amid the COVID-19 pandemic is expected to drive patient participation.

GlobalData conducted a survey to identify the biggest perceived benefits of decentralised clinical trials (DCTs) according to the companies, which did not implement DCTs previously but plan to conduct in future.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Transition to decentralised clinical trials expected to fuel patient participationPerceived Benefits of Decentralised Trials for Future Users

According to the survey results, around 17% of the respondents expect that the shift will lead to greater participation of patients, while 16% feel that it will increase participation of sites.

Around 14% noted that transitioning to DCTs will ensure that the clinical trials will continue to run during the COVID-19 pandemic.

The fourth highest voted reason is improved access to suitable trial patients (13%). It is followed by the perceived benefit of using different study designs involving more real world data and higher data volume (11%).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Approximately 10% of the respondents feel that the biggest benefit will be improved data quality to near time data collection and automation, while another 9% believes that switching to DCTs will reduce trial costs.

The percentage of respondents who opined that DCTs will reduce trial timeline stands at 6%.

Additionally, 3% of the respondents noted that it will lead to less complexities in running studies at sites and another 2% stated that will reduce technical complexities in using study related systems.

The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.